Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Posts 21 Percent Q4 Revenue Increase

NEW YORK, Feb. 17 (GenomeWeb News) - Qiagen today reported a 21 percent revenue increase, along with a rise in net income and R&D spending, for the fourth quarter ended Dec. 31, 2003.

The company posted revenues of $95.1 million for the fourth quarter of 2003, up from $78.4 million in the year-ago period.

Net income was $9.0 million for the quarter, compared to $1.8 million in the same quarter of 2002 - a 407 percent increase. Net income excluding the effect of relocation and restructuring costs increased 34 percent to $13.0 million from $9.7 million in the same period of 2002.

Qiagen spent $9.1 million on R&D during the fourth quarter, up from $7.7 million in the prior year.

As of Dec. 31, 2003, Qiagen had $99.0 million in cash and cash equivalents, compared to $44.9 million as of Dec. 31, 2002.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.